<DOC>
	<DOCNO>NCT01511562</DOCNO>
	<brief_summary>The purpose study find effect ( good and/or bad ) treatment chemotherapy stem cell transplant compare chemotherapy alone primary CNS B-cell lymphoma . Currently best treatment patient primary CNS B-cell lymphoma know .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Autologous Stem Cell Transplant Treating Patients With Central Nervous System B-Cell Lymphoma</brief_title>
	<detailed_description>Primary Objective : To compare two-year progression-free survival ( PFS ) patient treat myeloablative consolidation treatment strategy HDT/ASCT versus treat non-myeloablative consolidation chemotherapy cytarabine etoposide Secondary Objectives : 1 . To compare two-year event-free survival ( EFS ) patient treat consolidation HDT/ASCT versus treat consolidation chemotherapy consist etoposide cytarabine 2 . To compare overall survival ( OS ) patient treat consolidation HDT/ASCT versus treat consolidation chemotherapy consist etoposide cytarabine 3 . To assess toxicity associate consolidation HDT/ASCT versus consolidation consist etoposide cytarabine 4 . To determine diffusion MRI metric ( ADCmini , ADC25 % , ADCmean ) prior induction chemotherapy , one full induction chemotherapy cycle , end induction chemotherapy predictor response outcome ( CALGB 581101 ) 5 . To determine brain FDG-PET metric ( tumor SUV tumor versus background SUV ) prior induction chemotherapy , one full induction chemotherapy cycle , end induction chemotherapy predictor response outcome ( CALGB 581101 ) 6 . To determine whether low baseline ADC measurement associate short PFS OS ( CALGB 581101 ) 7 . To determine whether reduction tumor SUV &gt; 25 % brain FDG-PET/CT one cycle induction therapy associate improved PFS OS ( CALGB 581101 ) 8 . To determine IHC-based biomarkers predictive adverse prognosis ( CALGB 151113 ) 9 . To determine IHC-based biomarkers predictive favorable prognosis ( CALGB 151113 ) BCL6 ( B-cell CLL/lymphoma 6 ) , STAT 6 ( signal transducer activator transcription 6 , interleukin-4 induce ) 10 . To analyze tumor tissue gene expression profile , correlate profile treatment outcome ( CALGB 151113 ) 11 . To determine whether CSF proteome predictor outcome ( prognostic marker ) irrespective treatment arm ( CALGB 151113 ) ( IL-10 ( interleukin 10 ) C3 ( complement component 3 ) 12 . To assess neurocognitive function patient treat consolidation HDT/ASCT versus treat consolidation chemotherapy ( etoposide cytarabine ) measure serial administration International PCNSL Collaborative Group ( IPCG ) neurocognitive battery evaluate long-term survivorship difference two arm ( CALGB 71105 )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>1 . Documentation Disease : Diagnosis primary CNS diffuse large Bcell lymphoma confirm one following : brain biopsy resection , cerebrospinal fluid vitreous fluid . 2 . Other Lymphomas : Patients must evidence history nonHodgkin lymphoma ( NHL ) outside CNS . 3 . Previous Treatment : Patients must prior chemotherapy radiation therapy lymphoma . 4 . Age Patients must age 18 75 year . 5 . Karnofsky Performance Scale Patients must measure Karnofsky Performance Scale ≥ 30 ( ≥ 50 patient ages 6070 ) . 6 . Pregnancy Nursing Status Patients must nonpregnant nonnursing ; woman childbearing potential must negative serum urine pregnancy test 1014 day prior registration ; addition , woman men childbearing potential must commit use effective form contraception throughout participation study ; appropriate method birth control include abstinence , oral contraceptive , implantable hormonal contraceptive , double barrier method ( diaphragm plus condom ) 7 . HIV Patients must negative HIV serology . 8 . Hepatitis Patients must negative HCV serology ( unless HBsAb positive patient recently receive HBV vaccine , case HBcAb negative ) . All patient must screen hepatitis B infection start treatment . Those patient test positive hepatitis B closely monitor evidence active HBV infection hepatitis several month rituximab treatment . PCNSL patient history hepatitis B infection treat entecavir lamivudine ( physician discretion choice drug ) antiviral prophylaxis prevent hepatitis B reactivation . 9 . Organ Transplant Immunosuppressant Therapy Patient must history organ transplantation ongoing immunosuppressant therapy . 10 . Required Initial Laboratory Values : ANC ≥ 1500/mcL , AST ALT &lt; 2 x upper limit normal ( ULN ) , total bilirubin ≤ 3 mg/dL , creatinine clearance ≥ 50 mL/min , platelet count ≥ 100,000/mcL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>